86 related articles for article (PubMed ID: 21489085)
1. Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control.
Richter D; Mickel C; Acharya S; Brunel P; Militaru C
Int J Clin Pract; 2011 May; 65(5):613-23. PubMed ID: 21489085
[TBL] [Abstract][Full Text] [Related]
2. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
4. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Schweizer J; Ulmer HJ; Benduhn H; Klebs S
Curr Med Res Opin; 2011 Jan; 27(1):131-40. PubMed ID: 21117946
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
[TBL] [Abstract][Full Text] [Related]
8. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.
Axthelm C; Sieder C; Meister F; Kaiser E
Curr Med Res Opin; 2012 Jan; 28(1):69-78. PubMed ID: 22117838
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
[TBL] [Abstract][Full Text] [Related]
13. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Ritter S; Zhang J
Curr Med Res Opin; 2010 Dec; 26(12):2841-9. PubMed ID: 21062137
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
